| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 |
| Profit before tax | -2.7 | -1.2 |
| Net income | -2.7 | -1.2 |
| EPS (diluted, $ a share) | $-0.40 | $-0.48 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: CELZ. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Creative Medical Technology Holdings, Inc.: key numbers
- Share price
- $0.5201Close, Nov 16
- Market cap
- $3.95M
- Shares outstanding
- 7.6MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Creative Medical Technology Holdings, Inc.
All →Creative Medical Technology Holdings Nasdaq/NYSE Compliance Notice
Creative Medical Technology Holdings received a deficiency notice from Nasdaq on November 10, 2026, for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. The company has until May 10, 2027, to regain compliance by having its stock close at or above $1.00 for at least ten consecutive business days. The notice has no immediate impact on the listing of the company's common stock (CELZ).
- Counterparty
- The Nasdaq Stock Market
- Term
- 180 days
Creative Medical Technology Holdings M&A Deal with BioDefense, Inc.
Creative Medical Technology Holdings acquired 4,000,000 shares of BioDefense, Inc. from Creative Acquisition Corp. for $200,000 in cash and 1,000,000 shares of its own common stock. Following the transaction, the company owns 80% of BioDefense, Inc., making it a majority-owned subsidiary.
- Counterparty
- BioDefense, Inc.